Cite
Verbrugge SE, Al M, Assaraf YG, et al. Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors. Exp Hematol Oncol. 2013;2(1):2doi: 10.1186/2162-3619-2-2.
Verbrugge, S. E., Al, M., Assaraf, Y. G., Niewerth, D., van Meerloo, J., Cloos, J., van der Veer, M., Scheffer, G. L., Peters, G. J., Chan, E. T., Anderl, J. L., Kirk, C. J., Zweegman, S., Dijkmans, B. A., Lems, W. F., Scheper, R. J., de Gruijl, T. D., & Jansen, G. (2013). Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors. Experimental hematology & oncology, 2(1), 2. https://doi.org/10.1186/2162-3619-2-2
Verbrugge, Sue Ellen, et al. "Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors." Experimental hematology & oncology vol. 2,1 (2013): 2. doi: https://doi.org/10.1186/2162-3619-2-2
Verbrugge SE, Al M, Assaraf YG, Niewerth D, van Meerloo J, Cloos J, van der Veer M, Scheffer GL, Peters GJ, Chan ET, Anderl JL, Kirk CJ, Zweegman S, Dijkmans BA, Lems WF, Scheper RJ, de Gruijl TD, Jansen G. Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors. Exp Hematol Oncol. 2013 Jan 10;2(1):2. doi: 10.1186/2162-3619-2-2. PMID: 23305345; PMCID: PMC3560160.
Copy
Download .nbib